Using disease-modifying treatments in multiple sclerosis: Association of British Neurologists (ABN) 2024 guidance. [Review]

Rashid, W.; Ciccarelli, O.; Leary, SM.; Arun, T.; Doshi, A.; Evangelou, N.; Ford, HL.; Hobart, J.; Jacob, S.; Muraro, PA.; Murray, K.; Palace, J.; Dobson, R.

Using disease-modifying treatments in multiple sclerosis: Association of British Neurologists (ABN) 2024 guidance. [Review]

All Authors

Rashid, W.

Ciccarelli, O.

Leary, SM.

Arun, T.

Doshi, A.

Evangelou, N.

Ford, HL.

Hobart, J.

Jacob, S.

Muraro, PA.

Show 3 more

LTHT Author

Ford, Helen

LTHT Department

Neurosciences
Neurology

Publication Date

2025

Item Type

Journal Article
Review

Abstract

The Association of British Neurologists last published guidelines on disease-modifying treatment (DMT) in multiple sclerosis (MS) in 2015. Since then, additional DMTs have been licensed and approved for prescribing within the National Health Service for relapsing-remitting MS, early primary progressive MS and active secondary progressive MS. This updated guidance provides a consensus-based approach to using DMTs. We provide recommendations for eligibility, starting, monitoring, switching and stopping of DMTs; pregnancy; equitable access to DMT; autologous haemopoietic stem-cell transplantation; and use of generics. We highlight best practice where it exists and discuss future priorities.